NESS ZIONA, Israel, June 26, 2018 /PRNewswire/ — CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that it has received grant approval from the Israel Innovation Authority (IIA) to finance continued development of the Company’s proprietary rhCollagen-based formulations intended for use as BioInk for the […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone